BiotechTube

Itolizumab + EQ001 Placebo

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD

Trial Timeline

Apr 29, 2022 → May 12, 2025

NCT ID
NCT05263999

About Itolizumab + EQ001 Placebo

Itolizumab + EQ001 Placebo is a phase 3 stage product being developed by Biocon for Graft Versus Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05263999. Target conditions include Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease.

What happened to similar drugs?

20 of 20 similar drugs in Graft Versus Host Disease were approved

Approved (20) Terminated (1) Active (0)
✅Prograf + Methotrexate + CyclosporineAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅azathioprine + sirolimusAstellas PharmaApproved
✅Aspirin + TicagrelorAstraZenecaApproved
✅SugammadexMerckApproved
✅RuxolitinibNovartisApproved
✅CyclosporineNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05263999Phase 3Terminated

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors
ProductCompanyStageHype Score
Prograf + Methotrexate + CyclosporineAstellas PharmaApproved
43
AlefaceptAstellas PharmaPhase 2
27
tacrolimusAstellas PharmaApproved
43
Tacrolimus + TacrolimusAstellas PharmaPre-clinical
26
azathioprine + sirolimusAstellas PharmaApproved
43
EQ001 + EQ001 PlaceboBioconPhase 1/2
32
SHR0302Jiangsu Hengrui MedicinePhase 1
29
AcalabrutinibAstraZenecaPhase 2
39
Aspirin + TicagrelorAstraZenecaApproved
43
SugammadexMerckApproved
43
Efprezimod alfa + Methotrexate + Tacrolimus + PlaceboMerckPhase 2
35
RuxolitinibNovartisApproved
50
Imatinib Mesylate and NilotinibNovartisPhase 2
35
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
PredEverNovartisPhase 2
35
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
29
CyclosporineNovartisApproved
39
Everolimus + Tacrolimus + Mycophenolic acidNovartisApproved
39
1 + 2NovartisApproved
43
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte GlobulinNovartisApproved
43